ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by Actuarialon Oct 02, 2017 9:42am

69 Views

Post# 26765770

RE:History of Axovant ...

Again, Roivant/Axovant is nothing but a scam. Who is getting rich in this scam? Ramaswamy, his mother, and his brother - obtained tons of shares for free. At the end of the day, Ramaswamy is a hedge fund manager playing capital games but not a scientiest. Never expect his mother/brother being able to do R&D as well.

Bullboard Posts

Changing Europe’s dependency on HREE from China